Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
NCT04880785
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
121
Enrollment
OTHER
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
Sponsor
Fundacion SEIMC-GESIDA
Collaborators
[object Object]